(Total Views: 345)
Posted On: 08/13/2018 12:29:47 PM
Post# of 11803
I'm going to assume that DECN is running its clinical trials for GenChoice in South Korea. If GenChoice is currently in a clinical trail then the IRB has already approved the trail, which is a big first step. Also, I am going to assume that running clinical trials are expensive. However, I believe it is less expensive to run clinicals in South Korea than it is in the USA.
It really comes down to money. DECN isn't swimming in money, so KB has to be smart about where he's going to get the best bang for the buck.
These things don't always move as quickly as any of us want, including the CEO. KB appears to be steering the ship in the right direction. Getting PetSure instead of GenSure probably puts us in a better market...let's hope so.
By the way, more than 80% of clinical trials conducted in South Korea are global.
It really comes down to money. DECN isn't swimming in money, so KB has to be smart about where he's going to get the best bang for the buck.
These things don't always move as quickly as any of us want, including the CEO. KB appears to be steering the ship in the right direction. Getting PetSure instead of GenSure probably puts us in a better market...let's hope so.
By the way, more than 80% of clinical trials conducted in South Korea are global.
(1)
(0)
